Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2002-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an
immune response that will kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who
have stage III or stage IV melanoma that has not responded to previous treatment.